We are live on ! Find out more
APRE icon

Aprea Therapeutics

50 hedge funds and large institutions have $468M invested in Aprea Therapeutics in 2020 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 18 increasing their positions, 10 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

275% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 4

80% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 10

28% more funds holding

Funds holding: 3950 (+11)

0.12% more ownership

Funds ownership: 3.08%3.2% (+0.12%)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

21% less capital invested

Capital invested by funds: $591M → $468M (-$123M)

Holders
50
Holders Change
+11
Holders Change %
+28.21%
% of All Funds
1.1%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
15
Increased
18
Reduced
10
Closed
4
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Norges Bank
51
Norges Bank
Norway
-$688K -750 Closed
Millennium Management
52
Millennium Management
New York
-$291K -317 Closed
CIM
53
Coastal Investment Management
California
-$229K -250 Closed
Bank of Montreal
54
Bank of Montreal
Ontario, Canada
-$37K -41 Closed

APRE Hedge Fund Activity: Q1 2020 in Review

50 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q1 2020, worth a combined $468M — down 21% from $591M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new APRE positions and 4 closed out — a net gain of 11 holders — while 18 added to existing stakes and 10 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $32.4M. The largest seller was Janus Henderson Group, cutting an estimated $21.5M.

  • 50 institutional investors held Aprea Therapeutics (APRE) as of Q1 2020, up from 39 in Q4 2019.
  • Funds reported $468M of Aprea Therapeutics stock for Q1 2020, down 21% quarter-over-quarter.
  • 15 funds opened new Aprea Therapeutics positions in Q1 2020 and 4 closed out, a net change of +11 holders.
  • The largest Aprea Therapeutics buyer in Q1 2020 was Fidelity Investments, an estimated $32.4M added.
  • The largest Aprea Therapeutics seller in Q1 2020 was Janus Henderson Group, an estimated $21.5M sold.

Based on aggregated 13F filings for Q1 2020.